Lactose Intolerance and Intestinal Permability
Key facts
- Where
- Istanbul, TürkiyeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07424898, who can take part
Where in Türkiye
- Bezmialem Vakıf University Medical Faculty HospitalIstanbul, TürkiyeNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bezmialem Vakif University
- Trial code
- NCT07424898
- Record updated
- 25 February 2026
- Original description
"This study evaluates the interplay between lactose intolerance, intestinal barrier function (zonulin), and intestinal inflammation (fecal calprotectin) in adults, aiming to clarify their independent contributions to symptom severity and quality of life."Read full original descriptionShow less
Observational Cross-Sectional Study of Intestinal Permeability in Adults With Lactose Intolerance
"This study evaluates the interplay between lactose intolerance, intestinal barrier function (zonulin), and intestinal inflammation (fecal calprotectin) in adults, aiming to clarify their independent contributions to symptom severity and quality of life."
Inclusion: Adults aged 18-70 years; experiencing chronic symptoms (diarrhea, bloating, abdominal pain, constipation, flatulence) for the past 3 months, potentially fitting IBS criteria.
Exclusion: Acute gastroenteritis (< 4 weeks), Active gastrointestinal bleeding (stomach, small intestine, and colon), Known celiac disease, Bariatric surgery or short bowel syndrome, Pregnancy or lactation, Type I and II Diabetes mellitus, Antibiotic use within the last 2 weeks, High-dose NSAIDs within the last 2 weeks, Initiation of probiotics or prebiotics within the last 4 weeks, High-dose PPI use (optional), Inflammatory bowel disease (IBD; ulceretive colitis and Crohn's colitis) with active severe flare (excluded from primary analyses, evaluated separately in subgroup analyses).